LEUKEMIA IN 2019 AND BEYOND

State of the art, recent developments, and future directions in chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).

Faculty Chair

Elias Jabbour, MD

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Get a Sample of  This Report

Request a sample of this report and start discovering the insights

Report Topics Include

  • CML: First-Line TKI Landscape (including RFS/TFR)
    Kendra Sweet, MD
  • CML: Relapsed/Refractory and New Targets (including mutation testing)
    Richard Stone, MD
  • ALL: Genetic Subsets
    Charles Mullighan, MBBS, MSc, MD
  • ALL: Role of Monoclonal Antibodies
    Elias Jabbour, MD
  • ALL: Role of CAR T Cells
    Bijal Shah, MD
  • ALL: Measurable/Minimal Residual Disease
    Aaron Logan, MD, PhD
  • MDS: Low-Risk Disease
    Guillermo Garcia-Manero, MD
  • MDS: High-Risk Disease
    Keith Stewart, MB, ChB
  • AML: Patient Subsets (including ELN classification, prognostic groups, unfit elderly)
    Farhad Ravandi-Kashani, MD
  • AML: Targeting FLT3
    Richard Stone, MD
  • AML: New Therapeutic Targets
    Amir Fathi, MD
  • AML: Targeting BCL-2
    Naval Daver, MD

Medical Expert Panel

Elias Jabbour, MD

Naval Daver, MD

Amir Fathi, MD

Guillermo Garcia-Manero, MD

Rami Komrokji, MD

Aaron Logan, MD, PhD

Charles Mullighan, MBBS, MSc, MD

Farhad Ravandi-Kashani, MD

Bijal Shah, MD

Richard M. Stone, MD

Kendra Sweet, MD, MS

Srdan Verstovsek, MD, PhD

 

Explore Available and Upcoming Insight Reports

View Reports